• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2010 年的乳腺癌:针对个体化方法的新靶点和新疗法。

Breast cancer in 2010: Novel targets and therapies for a personalized approach.

机构信息

Massachusetts General Hospital Cancer Center, 55 Fruit Street, Laurence House, Boston, MA 02114, USA.

出版信息

Nat Rev Clin Oncol. 2011 Feb;8(2):65-6. doi: 10.1038/nrclinonc.2010.217.

DOI:10.1038/nrclinonc.2010.217
PMID:21278769
Abstract

2010 has been another prolific year in breast cancer research with a number of original observations bringing us closer to personalized care. Studies with novel targeted agents in defined breast cancer subgroups have revealed exciting developments and highlight the importance of patient selection.

摘要

2010 年在乳腺癌研究方面又是硕果累累的一年,许多新的观察结果使我们更接近个性化治疗。在明确的乳腺癌亚组中使用新型靶向药物的研究揭示了令人兴奋的进展,并强调了患者选择的重要性。

相似文献

1
Breast cancer in 2010: Novel targets and therapies for a personalized approach.2010 年的乳腺癌:针对个体化方法的新靶点和新疗法。
Nat Rev Clin Oncol. 2011 Feb;8(2):65-6. doi: 10.1038/nrclinonc.2010.217.
2
Breast cancer subtypes: morphologic and biologic characterization.乳腺癌亚型:形态学与生物学特征
Womens Health (Lond). 2016 Jan;12(1):103-19. doi: 10.2217/whe.15.99. Epub 2016 Jan 12.
3
Clinical Diagnosis and Management of Breast Cancer.《乳腺癌的临床诊断与管理》
J Nucl Med. 2016 Feb;57 Suppl 1:9S-16S. doi: 10.2967/jnumed.115.157834.
4
Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.新型乳腺癌个体化治疗策略:研究进展。
Int J Mol Sci. 2017 Nov 15;18(11):2423. doi: 10.3390/ijms18112423.
5
Dynamic strategy for personalized medicine: An application to metastatic breast cancer.个性化医疗的动态策略:在转移性乳腺癌中的应用
J Biomed Inform. 2017 Apr;68:50-57. doi: 10.1016/j.jbi.2017.02.012. Epub 2017 Feb 21.
6
Precision Medicine and Targeted Therapies in Breast Cancer.精准医学与乳腺癌的靶向治疗
Surg Oncol Clin N Am. 2020 Jan;29(1):51-62. doi: 10.1016/j.soc.2019.08.004. Epub 2019 Oct 29.
7
Cancer Evolution as the New Frontier of Precision Medicine.癌症演变作为精准医学的新前沿。
Handb Exp Pharmacol. 2018;249:289-297. doi: 10.1007/164_2018_147.
8
Innovations and Challenges in Breast Cancer Care: A Review.乳腺癌护理的创新与挑战:综述
Medicina (Kaunas). 2023 May 16;59(5):957. doi: 10.3390/medicina59050957.
9
Breast cancer personalized medicine: challenges and opportunities.乳腺癌个性化医疗:挑战与机遇
Am J Pathol. 2013 Oct;183(4):1036-1037. doi: 10.1016/j.ajpath.2013.08.001. Epub 2013 Aug 23.
10
Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer.基于基因组和转录异质性的乳腺癌个性化精准治疗
Per Med. 2019 Sep;16(5):361-364. doi: 10.2217/pme-2019-0036. Epub 2019 Sep 11.

引用本文的文献

1
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.2'-羟基黄烷酮通过靶向 RLIP76 抑制乳腺癌细胞的体外和体内生长。
Mol Carcinog. 2018 Dec;57(12):1751-1762. doi: 10.1002/mc.22894. Epub 2018 Sep 19.
2
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition.阿司匹林可阻断乳腺肿瘤细胞和肿瘤起始细胞的生长,并诱导间充质向上皮转化的重编程因子。
Lab Invest. 2015 Jul;95(7):702-17. doi: 10.1038/labinvest.2015.49. Epub 2015 Apr 13.
3
The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate.

本文引用的文献

1
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.曲妥珠单抗-DM1 抗体药物偶联物治疗曲妥珠单抗治疗后人表皮生长因子受体 2(HER2)阳性乳腺癌的 II 期研究。
J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20.
2
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.奥拉帕利在携带 BRCA1 或 BRCA2 突变的复发性卵巢癌患者中的疗效:一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.
3
多梳蛋白家族蛋白Bmi-1和Notch4在异硫氰酸苄酯抑制乳腺癌干细胞中的作用
Breast Cancer Res Treat. 2015 Feb;149(3):681-92. doi: 10.1007/s10549-015-3279-5. Epub 2015 Feb 8.
4
Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites.DNA 旁路聚合酶基因中的单核苷酸多态性及其与非裔美国人和白人乳腺癌及乳腺癌亚型的关联。
Breast Cancer Res Treat. 2015 Jan;149(1):181-90. doi: 10.1007/s10549-014-3203-4. Epub 2014 Nov 23.
5
Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells.Notch2激活对莪术二酮在人乳腺癌细胞中的抗癌作用具有保护作用。
Breast Cancer Res Treat. 2014 Aug;146(3):543-55. doi: 10.1007/s10549-014-3059-7. Epub 2014 Jul 20.
6
Association between vitamin D receptor poly(A) polymorphism and breast cancer risk: a meta-analysis.维生素D受体多聚腺苷酸多态性与乳腺癌风险的关联:一项荟萃分析。
Tumour Biol. 2014 Jan;35(1):589-93. doi: 10.1007/s13277-013-1082-7. Epub 2013 Sep 15.
7
Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk.尼美根断裂综合征1基因657del5多态性与乳腺癌风险之间的显著关联。
Tumour Biol. 2013 Oct;34(5):2753-7. doi: 10.1007/s13277-013-0830-z. Epub 2013 Jun 14.
8
Dietary chemopreventative benzyl isothiocyanate inhibits breast cancer stem cells in vitro and in vivo.膳食化学预防剂苄基异硫氰酸酯在体外和体内抑制乳腺癌干细胞。
Cancer Prev Res (Phila). 2013 Aug;6(8):782-90. doi: 10.1158/1940-6207.CAPR-13-0100. Epub 2013 May 9.
9
Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.苯甲基异硫氰酸酯抑制上皮-间充质转化过程中 FOXQ1 的表达。
Carcinogenesis. 2013 Apr;34(4):864-73. doi: 10.1093/carcin/bgs397. Epub 2012 Dec 30.
10
Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells.醉茄素 A 可激活人乳腺癌细胞中的 Notch2 和 Notch4。
Breast Cancer Res Treat. 2012 Nov;136(1):45-56. doi: 10.1007/s10549-012-2239-6. Epub 2012 Sep 11.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
奥拉帕利治疗携带 BRCA1 或 BRCA2 突变的晚期乳腺癌患者的疗效:一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6.
4
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.贝伐珠单抗联合多西他赛对比安慰剂联合多西他赛用于人表皮生长因子受体 2 阴性转移性乳腺癌一线治疗的 III 期研究。
J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457. Epub 2010 May 24.
5
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.曲妥珠单抗-DM1 的 I 期研究,一种 HER2 抗体药物偶联物,每 3 周给予 1 次,用于治疗 HER2 阳性转移性乳腺癌患者。
J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26.
6
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.曲妥珠单抗和帕妥珠单抗治疗曲妥珠单抗治疗后进展的人表皮生长因子受体 2 阳性转移性乳腺癌患者的 II 期临床试验。
J Clin Oncol. 2010 Mar 1;28(7):1138-44. doi: 10.1200/JCO.2009.24.2024. Epub 2010 Feb 1.
7
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.21 基因复发评分检测在化疗后淋巴结阳性、雌激素受体阳性乳腺癌绝经后妇女中的预后和预测价值:一项随机试验的回顾性分析。
Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.
8
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.紫杉醇联合贝伐单抗与单纯紫杉醇治疗转移性乳腺癌的比较
N Engl J Med. 2007 Dec 27;357(26):2666-76. doi: 10.1056/NEJMoa072113.